Point72 Asset Management
ACHN

Point72 Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Point72 Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-196,740
Closed -$313K – 1331
2018
Q4 		$313K Sell
196,740
-1,599,260
-89% -$4.52M ﹤0.01% 892
2018
Q3 		$6.61M Buy
+1,796,000
New +$5.35M 0.03% 540
2016
Q4 		– Sell
-7,054,346
Closed -$57.1M – 907
2016
Q3 		$57.1M Sell
7,054,346
-1,933,269
-22% -$16.4M 0.4% 50
2016
Q2 		$70.1M Sell
8,987,615
-116,306
-1% -$998K 0.48% 39
2016
Q1 		$70.3M Buy
9,103,921
+137,313
+2% +$1.01M 0.54% 36
2015
Q4 		$96.8M Sell
8,966,608
-805,410
-8% -$7.32M 0.8% 16
2015
Q3 		$67.5M Buy
9,772,018
+1,383,818
+16% +$11.3M 0.53% 36
2015
Q2 		$74.3M Buy
+8,388,200
New +$79.3M 0.51% 38
2015
Q1 		– Sell
-621,900
Closed -$7.62M – 849
2014
Q4 		$7.62M Sell
621,900
-426,200
-41% -$5.2M 0.05% 373
2014
Q3 		$10.5M Buy
1,048,100
+500,900
+92% +$4.65M 0.08% 280
2014
Q2 		$4.14M Buy
+547,200
New +$2.18M 0.03% 483

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management's ACHN Position: Q1 2019 in Review

Point72 Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 196,740 shares — an estimated $313K sold.

Point72 Asset Management first reported a position in ACHN in Q2 2014 and held it in 11 quarters. The position peaked at $96.8M in Q4 2015. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

  • Point72 Asset Management reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Point72 Asset Management sold 196,740 Achillion Pharmaceuticals shares in Q1 2019, an estimated $313K.
  • Point72 Asset Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 11 quarters.
  • Point72 Asset Management's Achillion Pharmaceuticals position peaked at $96.8M in Q4 2015.
  • 110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on Point72 Asset Management's 13F filing for Q1 2019, filed 15 May 2019.